February 24th 2022
DLBCL experts share their thoughts on the changing treatment landscape and emerging treatments in large B-cell lymphomas.
Panelists discuss data on the use of CAR T-cell therapies in earlier lines and implications of these data on the DLBCL treatment landscape going forward.
February 17th 2022
Dr Nowakowski shares data from CD19-targeting monoclonal antibodies in treatment of R/R DLBCL.
Dr Westin discusses real-world data with CAR T-cell therapies in R/R DLBCL that were presented at ASH 2021.
February 10th 2022
Dr Maziarz provides an overview of adverse events with CAR T-cell therapies and approaches to managing toxicities.
Panelists discuss data with CAR T-cell therapies in treatment of relapsed and refractory DLBCL.
February 3rd 2022
Dr Miklos provides an overview of chimeric antigen receptor T (CAR-T) cell therapy.
Dr Nowakowski discusses patient heterogeneity and treatment of relapsed vs refractory patients with DLBCL.
January 24th 2022
A panel of diffuse large B-cell lymphoma experts discuss patient criteria and treatment selection in relapsed/refractory DLBCL.
Drs Westin, Miklos, and other panelists discuss the standard of care and emerging frontline treatments for diffuse large B-cell lymphoma.
December 23rd 2021
A panel of oncologists talks about diffuse large B-cell lymphoma, what patient and disease factors one should take into account when thinking about DLBCL.
July 2nd 2020